Clinical Trials Logo

ECG clinical trials

View clinical trials related to ECG.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06335498 Completed - Atrial Fibrillation Clinical Trials

Further Study of AFGen1 Clinical Performance

CS3
Start date: April 2, 2024
Phase:
Study type: Observational

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish further evidence for the clinical performance of AFGen1 on human participants.

NCT ID: NCT06076798 Completed - Atrial Fibrillation Clinical Trials

Clinical Performance of AFGen1

Start date: October 5, 2023
Phase:
Study type: Observational

AFGen1 is indicated for use on symptomatic or asymptomatic adults who are at risk of developing or who have atrial fibrillation, where a software assisted analysis of ambulatory ECG is needed to identify episodes of Afib. The purpose of this study is to establish the clinical performance of AFGen1 on human participants.

NCT ID: NCT05591157 Completed - Healthy Clinical Trials

Evaluation of CSF-3 in Performing ECG

ECG
Start date: November 16, 2022
Phase: N/A
Study type: Interventional

CSF-3 is a wrist-worn medical device similar to a watch. It is designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings, using off-the-shelf ECG and unique PPG chipsets with proprietary algorithms. ECG and PPG are the two primary technologies for measuring heart rate. ECG measures the bio-potential generated by electrical signals that control the expansion and contraction of heart chambers, while PPG uses light-based technology to sense the rate of blood flow as controlled by the heart's pumping action.

NCT ID: NCT03727750 Completed - Pharmacokinetics Clinical Trials

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Start date: July 3, 2019
Phase: Phase 4
Study type: Interventional

This is a single-arm, open-label, Phase 4 study evaluating the effect of GO on the QTc, pharmacokinetics, safety, and immunogenicity of GO as a single-agent monotherapy in adult and pediatric patients with relapsed or refractory CD33-positive AML.

NCT ID: NCT03715361 Completed - Atrial Fibrillation Clinical Trials

AF Stroke Substudy SL-ECG Versus 12lead ECG

Start date: October 9, 2018
Phase:
Study type: Observational

The purpose of the study is to compare parameters obtained per SL-ECG with the values from 12lead-ECG measurement. Patients who undergo out- or inpatient treatment and who receive a 12lead-ECG are asked to participate in this examination. Furthermore, 50 patients without heart disease should be included (control group).